Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
2316 studies found for:    Myopathy
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Completed Evaluation of Patients With Statin Myopathy Using an N of 1 Trial Design
Condition: Statin Myopathy
Interventions: Drug: Individual-specific statin causing myopathy;   Drug: Placebo
2 Completed A Phase 2 Study to Evaluate the Dose and Pharmacodynamic Efficacy of Sialic Acid-Extended Release (SA-ER) Tablets in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy
Conditions: GNE Myopathy;   Hereditary Inclusion Body Myopathy
Interventions: Drug: Sialic Acid Extended Release (SA-ER);   Drug: Placebo
3 Recruiting Muscle Force Assessment in the Intensive Care Unit and in Primary Myopathies
Conditions: Sepsis;   Primary Myopathies
Intervention:
4 Completed Aerobic Training in Patients With Congenital Myopathies
Condition: Congenital Myopathy
Intervention: Other: Exercise on a cycle-ergometer
5 Active, not recruiting Respiratory Muscle Function in Untreated X-Linked Myotubular Myopathy (XLMTM)
Condition: X-linked Myotubular Myopathy
Interventions: Other: History and physical;   Other: Tidal breathing;   Other: Maximal respiratory pressures;   Other: Peak cough flow;   Other: Pediatric Evaluation of Disability Inventory;   Other: PedsQL Multidimensional Fatigue Scale;   Other: Review of ventilation requirements
6 Recruiting Myotubular Myopathy Genetic Testing Study
Condition: Myotubular Myopathy
Intervention: Other: Genetic Testing
7 Not yet recruiting Clinical Importance of Carrier Status of Recessive Gene Mutations in Myopathy (CICS)
Condition: Recessive Gene Myopathies
Intervention:
8 Recruiting Optimizing Treatment on Idiopathic Inflammatory Myopathies
Condition: Idiopathic Inflammatory Myopathies
Intervention: Drug: Intravenous Infusion
9 Recruiting RTA 408 Capsules in Patients With Mitochondrial Myopathy - MOTOR
Condition: MItochondrial Myopathies
Interventions: Drug: Omaveloxolone capsules, 2.5 mg;   Drug: omaveloxolone capsules, 5 mg;   Drug: omaveloxolone capsules, 10 mg;   Drug: Placebo capsules;   Drug: omaveloxolone capsules, 20 mg;   Drug: omaveloxolone capsules, TBD mg;   Drug: omaveloxolone capsules, 40 mg;   Drug: omaveloxolone capsules, 80 mg;   Drug: omaveloxolone capsules, 160 mg
10 Active, not recruiting Investigations Into ISCU Myopathy or Iron Sulfur Scaffold U Protein Myopathy
Condition: Myopathy
Intervention:
11 Unknown  The Association of Genetic Polymorphisms With Statin-Induced Myopathy.
Conditions: Rhabdomyolysis;   Myopathy
Intervention: Genetic: DNA
12 Recruiting Congenital Muscle Disease Study of Patient and Family Reported Medical Information
Conditions: Congenital Muscular Dystrophy (Including Unspecified/Undiagnosed);   Dystroglycanopathy;   Congenital Fiber Type Disproportion;   Rigid Spine Muscular Dystrophy;   Congenital Myopathy (Including Unspecified/Undiagnosed);   Collagen VI CMD (Ullrich CMD, Intermediate, Bethlem Myopathy);   Laminin Alpha 2 Related Congenital Muscular Dystrophy;   LAMA2-CMD/Merosin Deficient/MDC1A;   Walker-Warburg Syndrome;   Muscle-Eye-Brain Disease;   Fukuyama/Fukutin Related Muscular Dystrophy;   Integrin Alpha 7 Deficiency;   Integrin Alpha 9 Deficiency;   LMNA-CMD/Lamin A/C/Laminopathy;   SEPN1-Related Myopathy;   Bethlem Myopathy;   Actin Aggregation Myopathy;   Cap Disease;   Central Core Disease;   Centronuclear Myopathy;   Core Rod Myopathy;   Hyaline Body Myopathy;   Multiminicore Myopathy;   Myotubular Myopathy;   Nemaline Myopathy;   Tubular Aggregate Myopathy;   Zebra Body Myopathy;   Reducing Body Myopathy;   Spheroid Body Myopathy;   LGMD1B (LMNA);   LGMD1E (DES);   LGMD2G (TCAP);   LGMD2H (TRIM32);   LGMD2I (FKRP);   LGMD2J (TTN);   LGMD2K (POMT1);   LGMD2M (FKTN);   LGMD2N (POMT2);   LGMD2O (POMGnT1);   LGMD2P (DAG1);   LGMD2Q (PLEC1);   LGMD2R (DES);   LGMD2S (TRAPPC11);   LGMD2T (GMPPB);   LGMD2U (ISPD);   LGMD2V (GAA);   Ullrich Congenital Muscular Dystrophy;   Titinopathy;   Choline Kinase B Receptor;   Emery-Dreifuss Muscular Dystrophy;   RYR1 Related Myopathy;   SYNE1/Nesprin Related Muscular Dystrophy;   Telethonin Related Muscular Dystrophy (TCAP/Titin-Cap);   Congenital Myasthenic Syndrome;   Escobar Syndrome;   Myofibrillar Myopathy;   Malignant Hyperthermia;   Alpha-Dystroglycan Related Muscular Dystrophy (DAG1, DPM1, DPM2, DPM3, FKRP, FKTN);   Alpha-Dystroglycan Related Muscular Dystrophy (GAA, ISPD, LARGE, POMT1, POMT2, POMGnT1);   Alpha-Dystroglycan Related Muscular Dystrophy (Unspecified/Undiagnosed/Other)
Intervention:
13 Completed Myotubular Myopathy Event Study
Condition: X-linked Myotubular Myopathy
Intervention:
14 Active, not recruiting An Open Label Phase 2 Study of ManNAc in Subjects With GNE Myopathy
Condition: GNE Myopathy
Interventions: Drug: ManNac.;   Drug: ManNac
15 Completed Phase I Clinical Trial of ManNAc in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy (HIBM)
Conditions: Hereditary Inclusion Body Myopathy (HIBM);   GNE Myopathy
Intervention: Drug: ManNAc
16 Recruiting A Natural History Study of Patients With GNE Myopathy
Condition: Hereditary Inclusion Body Myopathy
Intervention:
17 Terminated Metabolic Features of Post-Myopathy Patients Associated With Statin Treatment
Condition: Myopathy (Statin Associated)
Intervention:
18 Unknown  Treatment of TNNT1-Myopathy With L-Tyrosine.
Condition: Nemaline Myopathy
Interventions: Drug: L-Tyrosine;   Drug: Placebo
19 Completed A Study Investigating the Safety, Tolerability, and Efficacy of MTP-131 for the Treatment of Mitochondrial Myopathy
Condition: Mitochondrial Myopathy
Interventions: Drug: MTP-131;   Drug: Placebo
20 Completed Intravenous Immune Globulin to Treat Hereditary Inclusion Body Myopathy
Condition: Hereditary Inclusion Body Myopathy
Intervention: Drug: Immune Globulin

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.